-
Outpatient Nirmatrelvir-Ritonavir and Remdesivir Utilization in Canada
Outpatient nirmatrelvir-ritonavir use varied across provinces. Remdesivir use, in the provinces for which utilization data was available, was low overall. Utilization of both therapies gradually decreased from October 2022, suggesting declining demand in this patient setting.
HC0069Utilization Analysis of Tofacitinib and Other Drugs Among Individuals with Ulcerative Colitis: Feasibility Analysis
It is not possible to draw conclusions about associations between the use of tofacitinib in ulcerative colitis and safety events due to the limited number of events observed. These findings suggest that detailed safety studies of tofacitinib in ulcerative colitis are currently not feasible in our data holdings.
OS0003Risk of Arterial and Venous Thrombotic Events Among Patients with COVID-19: A Multi-National Collaboration of Regulatory Agencies from Canada, Europe, and United States
The risk of arterial thromboembolism and venous thromboembolism among patients diagnosed with COVID-19 varied by country. This variation was observed among patients initially diagnosed in the ambulatory setting and the hospital setting, and before and during COVID-19 vaccine availability. Differences in healthcare systems, data sources, prevalence of underlying comorbid conditions, and approaches to COVID-19 and thromboembolism case definition may have contributed to the variation in thromboembolism risk estimates observed between countries.
Q20-21_CDMPrescription ranitidine use and population exposure in 6 Canadian provinces, 1996 to 2019: a serial cross-sectional analysis
In September 2019, Health Canada directed domestic manufacturers to cease distributing ranitidine due to potentially high concentrations of the possible carcinogen N-nitrosodimethylamine (NDMA). This study will characterize the use of dispensed histamine-2 receptor antagonists (H2RAs) in Canada by describing demographic and clinical characteristics of users and prescribers.
Q20-12Validity of diagnoses of SARS-CoV-2 infection in Canadian administrative health data: a multiprovince, population-based cohort study
This multi-province validation study supports the use of inpatient and ED records as alternatives to population- based laboratory tests for identification of COVID-19 cases during the first year of the pandemic.
Our findings do not support the use of outpatient service claims to identify people infected with COVID-19.Q21-04Hydrochlorothiazide use and risk of keratinocyte carcinoma and melanoma: A multisite population-based cohort study
The use of hydrochlorothiazide (HCTZ) was not associated with increased overall risks of keratinocyte carcinoma or melanoma when compared with angiotensin-converting enzyme inhibitors (ACEIs). However, elevated risks of keratinocyte carcinoma and melanoma were observed with longer durations of use (≥10 years) and higher cumulative doses (≥100,000 mg) of HCTZ, particularly when compared with calcium channel blockers (CCBs).